Abstract
PURPOSE: To evaluate the efficacy and safety of the Paul Glaucoma Implant (PGI) surgery in patients with secondary glaucomas. PATIENTS AND METHODS: Retrospective chart review of adult patients with medically recalcitrant secondary glaucoma who underwent PGI implantation at a single tertiary center between August 2022 and June 2023. The primary outcome measure was surgical success. Surgical success was defined as intraocular pressure (IOP) between 6 and 21 mmHg with a ≥20% reduction compared to baseline (with or without medications) with no need for implant removal, further glaucoma reoperation, or development of vision-threatening complications at 1 year of follow-up. The secondary outcomes were IOP, glaucoma medication numbers, visual acuity, and surgical complications. RESULTS: Thirty eyes of 30 patients were identified. Nine patients (30%) had neovascular glaucoma, and 9 patients (30%) had silicone-oil-induced glaucoma. At 12 months postoperatively, 28 eyes (93.3%) fulfilled the success criteria. The mean IOP at 12 months was 15.2 ± 4.6 mmHg compared to the mean baseline IOP of 32.6 ± 10 mmHg (p < 0.001). A significant reduction in the mean number of glaucoma medications at 12 months compared to the baseline was observed. The complication rate was 13.3% (4 eyes), with most complications being mild and transient. CONCLUSION: The PGI demonstrated favorable efficacy and safety profiles in the management of medically uncontrolled secondary glaucomas.